NecstGen at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

NecstGen brings 2 presentations to ESGCT 2026 in Hamburg. Its contribution is process development for cell and gene therapy manufacturing. Work covers a scalable downstream platform for retroviral and lentiviral vectors used in ex vivo gene therapy and a primary recovery step for Cas9 protein made in insect cells.

OrganizationESGCT 2026 Attendance
NecstGen
Leiden, Netherlands
necstgen.com
CDMOs & CROs
Non-profit contract development and manufacturing organization offering process development and GMP production for cell and gene therapies.
Poster
Wed Oct 28
1:30pm–3:30pm
A scalable retroviral and lentiviral vector downstream processing platform for ex vivo gene therapies
Manufacturing
Poster
Thu Oct 29
2:00pm–4:00pm
Development of a primary recovery process for scalable manufacturing of Cas9 produced using baculovirus expression vector system
Manufacturing

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from NecstGen

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction